Last updated 2026-07-20
- Acquired by Chemipal Ltd., Jul 2024
- Raised Seed round led by BIOLIGHT Life Sciences, Nov 2019
Total raised
—
Last: Undisclosed Round 2019-12
Stage
Seed
Founded
2016
Headcount
1
HQ
Ramat Gan, Israel
Sector
Health Tech & Life Sciences
About
LipiCare Pharmaceuticals develops products based on nano-emulsions of Phospholipids to deliver fatty medications to the ocular surface effectively and comfortably. The company's primary product is Ocular D, an eye drop for treating dry eye with integrated vitamin D, which also helps block blue light radiation.
Funding history · 1 round · — total
2019-11
Seed
Undisclosed
★ BIOLIGHT Life Sciences
Headcount over time
From 6 (2022-02) to 1 (2025-01) · -5 (-83%) · 3 points · source: Finder history + radar grounding
Q&A
- What is LipiCare Pharmaceuticals' primary focus?
- LipiCare Pharmaceuticals develops products based on nano-emulsions of phospholipids to effectively and comfortably deliver fatty medications to the ocular surface. The company is currently focused on Ocular D, a product for treating dry eyes with integrated vitamin D.
- When was LipiCare Pharmaceuticals founded?
- LipiCare Pharmaceuticals was founded in June 2016.
- What is LipiCare Pharmaceuticals' employee count?
- LipiCare Pharmaceuticals has 1-10 employees.
- Which company is LipiCare Pharmaceuticals a subsidiary of?
- LipiCare Pharmaceuticals is a subsidiary of Biolight.
- What is the status of LipiCare Pharmaceuticals' Ocular-D product development?
- Development of Ocular-D is being carried out by subcontractors, primarily an Italian manufacturer. LipiCare expects to commence production and marketing upon receiving CE approval in Europe for the product.
- What is the primary sector of LipiCare Pharmaceuticals?
- LipiCare Pharmaceuticals' primary sector is Health Tech & Life Sciences.
- Has LipiCare Pharmaceuticals secured any funding?
- Yes, LipiCare Pharmaceuticals received funding in December 2019 from BIOLIGHT Life Sciences.
- What additional protection might Ocular D provide?
- Laboratory testing has shown that Ocular D may help block blue light radiation, potentially offering additional protection to the eye beyond the benefits of the nano-emulsion itself.
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrug Delivery
Technologies
BiologicalsMolecules
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticalsHealthcareProvidersCommerce & RetailDistribution ChannelsDistributor
Business model
B2B2CB2B
Highlights
1 Patents
Tags
treatmentsophthalmologymedical-productsdrug-deliverypharmaceuticals
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | bio-light.co.il/lipicare-2 |
|---|---|
| linkedin.com/company/80939863 |
Identifiers & details
| Legal name | LipiCare Pharmaceuticals Ltd. |
|---|---|
| Founded | 2016-6 |
| Employees (exact) | 1 |
Acquisitions & public offerings
Acquired by Chemipal Ltd. 2024-07
Radar intelligence
Web history (Wayback)
| Domain | bio-light.co.il |
|---|
Certificate / subdomain footprint
| Subdomains | 1 |
|---|
Israeli Companies Registrar (רשם החברות / ICA)
| Registrar # (ח.פ.) | 515474385 |
|---|---|
| Status | פעילה |
| Corp type | ישראלית חברה פרטית |
| Incorporated | 2016-06-29 |
| Purpose | לעסוק בכל עיסוק חוקי |
| Liability | מוגבלת |
| In violation (unfiled) | no |
| Last annual report | 2025 |
| Active charges / liens | 0 |
| Registry events | 0 |
| Registered address | דרך אבא הלל 12 רמת גן |